Etoposide in patients with rheuma-associated hemophagocytic lymphohistiocytosis / macrophage activation syndrome by Henter, Jan-Inge et al.
POSTER PRESENTATION Open Access
Etoposide in patients with rheuma-associated
hemophagocytic lymphohistiocytosis /
macrophage activation syndrome
Jan-Inge Henter
1, AnnaCarin Horne
1,2*, Bo Magnusson
2, Stefan Hagelberg
2
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Background/aim
Rheuma-associated hemophagocytic lymphohistiocytosis
(Rh-HLH), also called macrophage activation syndrome
(MAS), is a severe complication of systemic inflamma-
tory disorders. Rh-HLH has clinical and laboratory simi-
larities to other forms of HLH, and is potentially life
threatening. Treatment of Rh-HLH has not been stan-
dardized yet, but it commonly includes a variety of
agents such as high-dose corticosteroids, cyclosporine,
intravenous immunoglobulin and, in severe cases, some-
times etoposide. Here we report on the experience of
etoposide in two children with severe Rh-HLH admitted
to the Karolinska Children’s Hospital over the 6 months
July 2010 to Dec 2010.
Methods
1) A 16-yr old boy with systemic lupus erythematosus
was referred from the local hospital because of acceler-
ating inflammatory disease. He was initially administered
methyl-prednisolone (MP) pulses for 3 days followed by
prednisolone 90 mg daily. He developed clinically signs
of severe CNS-affection, confirmed by MRI, and diag-
nostic criteria consistent with MAS. Treatment with
etoposide 75 mg/m2 weekly was administered for a
month. His CNS symptoms rapidly improved, he recov-
ered fully and a subsequent MRI was normal.
2) A 9-yr old girl with systemic juvenile idiopathic
arthritis on treatment with tocilizumab and oral metho-
trexate was infected with EBV. She developed a fulmi-
nant picture of MAS. She was initially administered
MP-pulses. However, within 24 hours her cerebral func-
tion deteriorated further, and therapy was intensified
with etoposide 100 mg/m2 (a total of 8 courses), rituxi-
mab 375 mg/m2 and dexamethasone. She also devel-
oped seizures and an abnormal MRI. She recovered
fully, and a subsequent MRI was normal.
Results
Two children with Rh-HLH and CNS affection both
responded well and without severe side effects to weekly
etoposide 75-100 mg/m2 as a complement to high-dose
MP pulses.
Conclusion
Etoposide is worth considering in severe Rh-HLH.
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